SCHEMBL3777905

SCHEMBL3777905

Cc1nc2c(Cl)ccc(C#N)c2c(C)c1Cc1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 7/20 0.39
KMT2A Q03164 1/20 0.38
THRB P10828 1/20 0.38
ENPP2 Q13822 1/20 0.37
ENPP1 P22413 1/20 0.36
MBOAT4 Q96T53 2/20 0.35
KDM4E B2RXH2 3/20 0.35
GAA P10253 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
FPR1 P21462 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
ALDH1A1 P00352 2/20 0.33
HTT P42858 2/20 0.33
HPGD P15428 1/20 0.33
NPC1 O15118 1/20 0.33
NCOA1 Q15788 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3775557 0.81 KMT2A (0.40) KMT2AENPP2ENPP1KDM4EALDH1A1
SCHEMBL3781037 0.80 KMT2A (0.35) KMT2ATHRBENPP2ENPP1KDM4E
SCHEMBL3771013 0.75 EGLN1 (0.39) KMT2AENPP2KDM4ECYP2C9ALDH1A1
SCHEMBL27826435 0.74 KDM4E (0.38) KMT2AENPP2ENPP1KDM4ECYP2D6
SCHEMBL3779168 0.72 TDP1 (0.45) THRBTDP1
SCHEMBL3781729 0.72 ALDH1A1 (0.41) KMT2AMBOAT4KDM4EALDH1A1HPGD
SCHEMBL27722729 0.72 LMNA (0.37) KMT2AENPP2KDM4EGAACYP2D6
SCHEMBL3782858 0.72 KMT2A (0.37) KMT2AENPP2ENPP1KDM4EALDH1A1
SCHEMBL3783401 0.71 TSHR (0.48)
SCHEMBL3778339 0.71 ENPP2 (0.38) KMT2AENPP2ENPP1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
CN-101316591-B Quinoline compound and pharmaceutical application thereof ARGENTA ORAL THERAPEUTICS LTD. (GB) 2012-02-01 CN disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
CN-101316591-A Quinolines and their therapeutic use ARGENTA DISCOVERY LTD (GB) 2008-12-03 CN disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 AR 1069/4885KMT2A 3406/4885THRB 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.